DongKi Lee - OliX PharmaceuticalsI CEO Director
| 226950 Stock | 43,400 2,700 5.86% |
Insider
DongKi Lee is CEO Director of OliX PharmaceuticalsInc
| Age | 51 |
| Phone | 82 3 1779 8400 |
| Web | http://www.olixpharma.com |
OliX PharmaceuticalsI Management Efficiency
The company has return on total asset (ROA) of (0.164) % which means that it has lost $0.164 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (76.6277) %, meaning that it generated substantial loss on money invested by shareholders. OliX PharmaceuticalsI's management efficiency ratios could be used to measure how well OliX PharmaceuticalsI manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| SeungBum Park | Medy Tox | 54 | |
| Young Cho | LegoChem Biosciences | N/A | |
| SoJin Ahn | Oscotec | N/A | |
| YongIn Kim | Medy Tox | 61 | |
| SungHee Son | Oscotec | N/A | |
| HeeSeok Joo | Medy Tox | 57 | |
| Hirose Dakashi | Oscotec | N/A | |
| You WeonKyoo | ABL Bio | N/A | |
| Jae Jung | ABL Bio | N/A | |
| Ho Song | LegoChem Biosciences | N/A | |
| Jaecheon Lee | ABL Bio | N/A | |
| SuSung Lee | Oscotec | N/A | |
| HyunHo Jung | Medy Tox | 61 | |
| Dae Lee | LegoChem Biosciences | N/A | |
| Jong Won | ABL Bio | N/A | |
| JuWon Kim | Oscotec | N/A | |
| Sang Lee | ABL Bio | N/A | |
| Yeong Oh | LegoChem Biosciences | 64 | |
| JaeSang Lee | Oscotec | N/A | |
| SungHo Park | Oscotec | 55 | |
| YongZu Kim | LegoChem Biosciences | 67 | |
Management Performance
| Return On Equity | -76.63 | |||
| Return On Asset | -0.16 |
OliX PharmaceuticalsInc Management Team
Elected by the shareholders, the OliX PharmaceuticalsI's board of directors comprises two types of representatives: OliX PharmaceuticalsI inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OliX. The board's role is to monitor OliX PharmaceuticalsI's management team and ensure that shareholders' interests are well served. OliX PharmaceuticalsI's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OliX PharmaceuticalsI's outside directors are responsible for providing unbiased perspectives on the board's policies.
| SunWoo Hong, VP Director | ||
| Shin Park, Sr Devel | ||
| DongKi Lee, CEO Director |
OliX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OliX PharmaceuticalsI a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -76.63 | |||
| Return On Asset | -0.16 | |||
| Operating Margin | (6.56) % | |||
| Current Valuation | 576.53 B | |||
| Shares Outstanding | 6.51 M | |||
| Shares Owned By Insiders | 29.21 % | |||
| Shares Owned By Institutions | 6.02 % | |||
| Price To Sales | 75.58 X | |||
| Revenue | 3.67 B | |||
| Gross Profit | 2.42 B |
Other Information on Investing in OliX Stock
OliX PharmaceuticalsI financial ratios help investors to determine whether OliX Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in OliX with respect to the benefits of owning OliX PharmaceuticalsI security.